It may be old news, but it is very good news; the FDA has just licensed fingolimod as the first DMT for paediatric MS. I am sure parents of children with MS living in the US are relieved that they finally have a licensed therapy for their children. I sincerely hope the EMA now steps up to the mark and does the same in Europe.
As a reminder, the following are the headline results from the study that were presented at ECTRIMS last year. It is clear that fingolimod is far superior to interferon-beta in this younger population.